Drug Profile
Gentuximab injection - GeneScience Pharmaceuticals
Latest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator GeneScience Pharmaceuticals
- Developer GeneScience Pharmaceuticals; Shanghai East Hospital
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gastric cancer
- Phase I Non-small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in China (IV, Injection)
- 14 Aug 2019 GeneScience Pharmaceuticals plans a phase Ib/II trial of gentuximab and paclitaxel for Gastric or Gastroesophageal cancer (Late stage disease, Combination therapy) in China, in August 2019 (NCT04053205)
- 11 Oct 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy, Metastatic disease, In adults, In the elderly) in China (IV) (NCT03313219)